company background image
WVE

Wave Life Sciences NasdaqGM:WVE Stock Report

Last Price

US$4.24

Market Cap

US$368.5m

7D

0.7%

1Y

15.5%

Updated

01 Dec, 2022

Data

Company Financials +
WVE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

WVE Stock Overview

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform.

Wave Life Sciences Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Wave Life Sciences
Historical stock prices
Current Share PriceUS$4.24
52 Week HighUS$5.31
52 Week LowUS$1.16
Beta-0.50
1 Month Change-11.48%
3 Month Change44.22%
1 Year Change15.53%
3 Year Change-88.01%
5 Year Change-88.30%
Change since IPO-73.50%

Recent News & Updates

Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates

Nov 11
Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates

Recent updates

Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates

Nov 11
Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Aug 12
Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?

Apr 21
Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?

Jan 11
Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?

We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully

Sep 24
We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully

What Does The Future Hold For Wave Life Sciences Ltd. (NASDAQ:WVE)? These Analysts Have Been Cutting Their Estimates

Aug 07
What Does The Future Hold For Wave Life Sciences Ltd. (NASDAQ:WVE)? These Analysts Have Been Cutting Their Estimates

Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Slashed This Year's Estimates

May 15
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Slashed This Year's Estimates

Things Look Grim For Wave Life Sciences Ltd. (NASDAQ:WVE) After Today's Downgrade

Apr 02
Things Look Grim For Wave Life Sciences Ltd. (NASDAQ:WVE) After Today's Downgrade

Wave Life Sciences (NASDAQ:WVE) Share Prices Have Dropped 80% In The Last Three Years

Feb 19
Wave Life Sciences (NASDAQ:WVE) Share Prices Have Dropped 80% In The Last Three Years

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Jan 13
Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Here's What We Think About Wave Life Sciences' (NASDAQ:WVE) CEO Pay

Dec 08
Here's What We Think About Wave Life Sciences' (NASDAQ:WVE) CEO Pay

Shareholder Returns

WVEUS PharmaceuticalsUS Market
7D0.7%2.0%1.5%
1Y15.5%14.1%-14.8%

Return vs Industry: WVE exceeded the US Pharmaceuticals industry which returned 13% over the past year.

Return vs Market: WVE exceeded the US Market which returned -18.9% over the past year.

Price Volatility

Is WVE's price volatile compared to industry and market?
WVE volatility
WVE Average Weekly Movement13.5%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: WVE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: WVE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2012237Paul B. Bolnohttps://www.wavelifesciences.com

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington’s disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders.

Wave Life Sciences Ltd. Fundamentals Summary

How do Wave Life Sciences's earnings and revenue compare to its market cap?
WVE fundamental statistics
Market CapUS$368.46m
Earnings (TTM)-US$152.90m
Revenue (TTM)US$4.18m

88.3x

P/S Ratio

-2.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
WVE income statement (TTM)
RevenueUS$4.18m
Cost of RevenueUS$103.27m
Gross Profit-US$99.10m
Other ExpensesUS$53.80m
Earnings-US$152.90m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.76
Gross Margin-2,373.58%
Net Profit Margin-3,662.25%
Debt/Equity Ratio0%

How did WVE perform over the long term?

See historical performance and comparison